ALFA Finder
Wed, 4 Nov
Biocon
Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
Summary ready
Earnings calls
Biocon concalls
Every Biocon earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
Outlook
H2 guided stronger than H1 with 'strong double-digit' USD growth; Brazil supplies begin Q4FY27, full run-rate FY28.
Earlier call summaries
All →
08:29 IST
BSE
Earnings Call
Biocon Earnings Call: Key Takeaways
Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.
16:27 IST
BSE
Earnings Call
Biocon Earnings Call: Key Takeaways
Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.
21:31 IST
BSE
Earnings Call
Biocon Earnings Call: Key Takeaways
Biocon Q3FY26 reports 9% operating revenue growth at Rs 4,173 Cr and 475% increase in Net Profit to Rs 144 Cr, driven by Biosimilars and Generics momentum.
08:16 IST
BSE
Earnings Call
Biocon Earnings Call: Key Takeaways
Biocon reported FY26 revenue of ₹16,927 Cr (+13% YoY adjusted). Transitioning from investment phase to execution, focusing on margin expansion and deleveraging across Biosimilars, Generics, and CRDMO.
Biocon Limited: key numbers
- Share price
- ₹371.15
- Market cap
- ₹60,486 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 133.8×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.